SMN1 and proximal spinal muscular atrophy: We used the histone deacetylase inhibitor valproic acid (VPA), which was previously demonstrated to increase SMN levels in human SMA fibroblasts [55], [56], leading to improved motor function and survival in a mouse model of SMA [57].